The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship.
Cancer
Cohort study
Disparities
Genetic
Survivorship
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Feb 2022
25 Feb 2022
Historique:
received:
23
09
2021
accepted:
21
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
18
3
2022
Statut:
epublish
Résumé
The Kaiser Permanente Research Bank (KPRB) is collecting biospecimens and surveys linked to electronic health records (EHR) from approximately 400,000 adult KP members. Within the KPRB, we developed a Cancer Cohort to address issues related to cancer survival, and to understand how genetic, lifestyle and environmental factors impact cancer treatment, treatment sequelae, and prognosis. We describe the Cancer Cohort design and implementation, describe cohort characteristics after 5 years of enrollment, and discuss future directions. Cancer cases are identified using rapid case ascertainment algorithms, linkage to regional or central tumor registries, and direct outreach to KP members with a history of cancer. Enrollment is primarily through email invitation. Participants complete a consent form, survey, and donate a blood or saliva sample. All cancer types are included. As of December 31, 2020, the cohort included 65,225 cases (56% female, 44% male) verified in tumor registries. The largest group was diagnosed between 60 and 69 years of age (31%) and are non-Hispanic White (83%); however, 10,076 (16%) were diagnosed at ages 18-49 years, 4208 (7%) are Hispanic, 3393 (5%) are Asian, and 2389 (4%) are Black. The median survival time is 14 years. Biospecimens are available on 98% of the cohort. The KPRB Cancer Cohort is designed to improve our understanding of treatment efficacy and factors that contribute to long-term cancer survival. The cohort's diversity - with respect to age, race/ethnicity and geographic location - will facilitate research on factors that contribute to cancer survival disparities.
Sections du résumé
BACKGROUND
BACKGROUND
The Kaiser Permanente Research Bank (KPRB) is collecting biospecimens and surveys linked to electronic health records (EHR) from approximately 400,000 adult KP members. Within the KPRB, we developed a Cancer Cohort to address issues related to cancer survival, and to understand how genetic, lifestyle and environmental factors impact cancer treatment, treatment sequelae, and prognosis. We describe the Cancer Cohort design and implementation, describe cohort characteristics after 5 years of enrollment, and discuss future directions.
METHODS
METHODS
Cancer cases are identified using rapid case ascertainment algorithms, linkage to regional or central tumor registries, and direct outreach to KP members with a history of cancer. Enrollment is primarily through email invitation. Participants complete a consent form, survey, and donate a blood or saliva sample. All cancer types are included.
RESULTS
RESULTS
As of December 31, 2020, the cohort included 65,225 cases (56% female, 44% male) verified in tumor registries. The largest group was diagnosed between 60 and 69 years of age (31%) and are non-Hispanic White (83%); however, 10,076 (16%) were diagnosed at ages 18-49 years, 4208 (7%) are Hispanic, 3393 (5%) are Asian, and 2389 (4%) are Black. The median survival time is 14 years. Biospecimens are available on 98% of the cohort.
CONCLUSIONS
CONCLUSIONS
The KPRB Cancer Cohort is designed to improve our understanding of treatment efficacy and factors that contribute to long-term cancer survival. The cohort's diversity - with respect to age, race/ethnicity and geographic location - will facilitate research on factors that contribute to cancer survival disparities.
Identifiants
pubmed: 35216576
doi: 10.1186/s12885-022-09252-6
pii: 10.1186/s12885-022-09252-6
pmc: PMC8876075
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
Cancer Causes Control. 2016 Nov;27(11):1315-1323
pubmed: 27639398
Lancet Oncol. 2017 Nov;18(11):e653-e706
pubmed: 29208398
J Natl Cancer Inst. 2007 Sep 19;99(18):1384-94
pubmed: 17848670
BMC Pregnancy Childbirth. 2016 Nov 29;16(1):381
pubmed: 27899076
Nat Rev Clin Oncol. 2016 Feb;13(2):92-105
pubmed: 26391778
PLoS One. 2018 Jul 25;13(7):e0201034
pubmed: 30044829
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Proc Annu Symp Comput Appl Med Care. 1993;:695-9
pubmed: 8130565
Cancer. 2007 Apr 15;109(8):1607-16
pubmed: 17343277
J Clin Oncol. 2015 Mar 10;33(8):877-84
pubmed: 25667279
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
J Natl Cancer Inst. 2015 Oct 12;107(12):djv279
pubmed: 26464424
J Natl Cancer Inst. 2019 Feb 1;111(2):109-117
pubmed: 30657942
JAMA Intern Med. 2017 Jul 1;177(7):1003-1011
pubmed: 28492829
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Genetics. 2015 Aug;200(4):1051-60
pubmed: 26092718
J Clin Oncol. 2013 Jul 20;31(21):2708-15
pubmed: 23775966
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
EGEMS (Wash DC). 2014 Mar 24;2(1):1049
pubmed: 25848584
N Engl J Med. 2015 Feb 26;372(9):793-5
pubmed: 25635347
J Natl Cancer Inst Monogr. 2005;(35):12-25
pubmed: 16287881
J Natl Cancer Inst. 2006 Apr 19;98(8):504-5
pubmed: 16622113